Sphingomyelin synthase 1 activity is regulated by the BCR-ABL oncogene[S]

Sphingomyelin synthase (SMS) produces sphingomyelin while consuming ceramide (a negative regulator of cell proliferation) and forming diacylglycerol (DAG) (a mitogenic factor). Therefore, enhanced SMS activity could favor cell proliferation. To examine if dysregulated SMS contributes to leukemogenesis, we measured SMS activity in several leukemic cell lines and found that it is highly elevated in K562 chronic myelogenous leukemia (CML) cells. The increased SMS in K562 cells was caused by the presence of Bcr-abl, a hallmark of CML; stable expression of Bcr-abl elevated SMS activity in HL-60 cells while inhibition of the tyrosine kinase activity of Bcr-abl with Imatinib mesylate decreased SMS activity in K562 cells. The increased SMS activity was the result of up-regulation of the Sms1 isoform. Inhibition of SMS activity with D609 (a pharmacological SMS inhibitor) or down-regulation of SMS1 expression by siRNA selectively inhibited the proliferation of Bcr-abl-positive cells. The inhibition was associated with an increased production of ceramide and a decreased production of DAG, conditions that antagonize cell proliferation. A similar change in lipid profile was also observed upon pharmacological inhibition of Bcr-abl (K526 cells) and siRNA-mediated down-regulation of BCR-ABL (HL-60/Bcr-abl cells). These findings indicate that Sms1 is a downstream target of Bcr-abl, involved in sustaining cell proliferation of Bcr-abl-positive cells.

[1]  M. Dimanche-Boitrel,et al.  Targeting the ceramide system in cancer. , 2013, Cancer letters.

[2]  L. Obeid,et al.  Ceramide and apoptosis: exploring the enigmatic connections between sphingolipid metabolism and programmed cell death. , 2012, Anti-cancer agents in medicinal chemistry.

[3]  S. Summers,et al.  Ceramides as modulators of cellular and whole-body metabolism. , 2011, The Journal of clinical investigation.

[4]  K. Schulze-Osthoff,et al.  Caspase-mediated inhibition of sphingomyelin synthesis is involved in FasL-triggered cell death , 2010, Cell Death and Differentiation.

[5]  J. Melo,et al.  Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-γ1-driven activation of mTOR/p70S6-kinase pathway , 2010, Oncogene.

[6]  M. Tani,et al.  Sphingomyelin synthase 2 is palmitoylated at the COOH-terminal tail, which is involved in its localization in plasma membranes. , 2009, Biochemical and biophysical research communications.

[7]  Jorge Cortes,et al.  Molecular biology of bcr-abl1-positive chronic myeloid leukemia. , 2009, Blood.

[8]  P. Lu,et al.  Ceramide synthase 6 modulates TRAIL sensitivity and nuclear translocation of active caspase 3 in colon cancer cells , 2008, Oncogene.

[9]  M. Konopleva,et al.  Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK , 2008, Cell cycle.

[10]  Renxiao Wang,et al.  The domain responsible for sphingomyelin synthase (SMS) activity. , 2008, Biochimica et biophysica acta.

[11]  M. Del Poeta,et al.  Sphingomyelin synthases regulate production of diacylglycerol at the Golgi. , 2008, The Biochemical journal.

[12]  A. Tarca,et al.  Suppression of sphingomyelin synthase 1 by small interference RNA is associated with enhanced ceramide production and apoptosis after photodamage. , 2008, Experimental cell research.

[13]  J. Melo,et al.  Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells , 2008, Leukemia.

[14]  F. Maxfield,et al.  SMS overexpression and knockdown: impact on cellular sphingomyelin and diacylglycerol metabolism, and cell apoptosis Published, JLR Papers in Press, November 2, 2007. , 2008, Journal of Lipid Research.

[15]  J. Sessions Chronic myeloid leukemia in 2007. , 2007, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[16]  J. Apperley Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. , 2007, The Lancet. Oncology.

[17]  D. Peake,et al.  Inhibition of sphingomyelin synthase (SMS) affects intracellular sphingomyelin accumulation and plasma membrane lipid organization. , 2007, Biochimica et biophysica acta.

[18]  M. Tainsky,et al.  Sphingomyelin synthase 1 suppresses ceramide production and apoptosis post-photodamage. , 2007, Biochemical and biophysical research communications.

[19]  Martin Hermansson,et al.  Both Sphingomyelin Synthases SMS1 and SMS2 Are Required for Sphingomyelin Homeostasis and Growth in Human HeLa Cells* , 2007, Journal of Biological Chemistry.

[20]  L. Obeid,et al.  Alterations of Ceramide/Sphingosine 1-Phosphate Rheostat Involved in the Regulation of Resistance to Imatinib-induced Apoptosis in K562 Human Chronic Myeloid Leukemia Cells* , 2007, Journal of Biological Chemistry.

[21]  M. Kazanietz,et al.  Protein kinase C and other diacylglycerol effectors in cancer , 2007, Nature Reviews Cancer.

[22]  Y. Hannun,et al.  Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas , 2007, Molecular Cancer Therapeutics.

[23]  J. Dutcher,et al.  Blastic phase of chronic myelogenous leukemia , 2005, Current treatment options in oncology.

[24]  S. Marley,et al.  Chronic myeloid leukaemia: stem cell derived but progenitor cell driven. , 2005, Clinical science.

[25]  R. Ren,et al.  Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia , 2005, Nature Reviews Cancer.

[26]  Jacek Bielawski,et al.  Role for Mammalian Neutral Sphingomyelinase 2 in Confluence-induced Growth Arrest of MCF7 Cells* , 2004, Journal of Biological Chemistry.

[27]  B. Druker,et al.  Lessons learned from the development of imatinib. , 2004, Leukemia research.

[28]  Shohei Yamaoka,et al.  Expression Cloning of a Human cDNA Restoring Sphingomyelin Synthesis and Cell Growth in Sphingomyelin Synthase-defective Lymphoid Cells* , 2004, Journal of Biological Chemistry.

[29]  O. Witte,et al.  The BCR-ABL story: bench to bedside and back. , 2004, Annual review of immunology.

[30]  H. Umehara,et al.  Increase of Nuclear Ceramide through Caspase-3-Dependent Regulation of the “Sphingomyelin Cycle” in Fas-Induced Apoptosis , 2004, Cancer Research.

[31]  J. Brouwers,et al.  Identification of a family of animal sphingomyelin synthases , 2004, The EMBO journal.

[32]  N. Ridgway,et al.  The role of de novo ceramide synthesis in the mechanism of action of the tricyclic xanthate D609 Published, JLR Papers in Press, September 16, 2003. DOI 10.1194/jlr.M300300-JLR200 , 2004, Journal of Lipid Research.

[33]  Y. Hannun,et al.  BcR-induced Apoptosis Involves Differential Regulation of C16 and C24-Ceramide Formation and Sphingolipid-dependent Activation of the Proteasome* , 2003, The Journal of Biological Chemistry.

[34]  A. Ganser,et al.  Specific inhibition of bcr-abl gene expression by small interfering RNA. , 2003, Blood.

[35]  T. Uchiyama,et al.  Possible role of ceramide as an indicator of chemoresistance: decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  O. Linder,et al.  Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase – a report from the Swedish CML Group , 2002, British journal of haematology.

[37]  H. Kantarjian,et al.  Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. , 2002, Blood.

[38]  D. Marin,et al.  The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations. , 2002, Haematologica.

[39]  L. Riboni,et al.  Basic Fibroblast Growth Factor-induced Proliferation of Primary Astrocytes , 2001, The Journal of Biological Chemistry.

[40]  J. Melo,et al.  The molecular biology of chronic myeloid leukemia. , 2000, Blood.

[41]  G. Müller,et al.  Tumor Necrosis Factor Induces Ceramide Oscillations and Negatively Controls Sphingolipid Synthases by Caspases in Apoptotic Kym-1 Cells* , 1998, The Journal of Biological Chemistry.

[42]  V. Maguer-Satta CML and apoptosis: the ceramide pathway. , 1998, Hematology and cell therapy.

[43]  Y. Hannun,et al.  Sphingomyelin Synthase, a Potential Regulator of Intracellular Levels of Ceramide and Diacylglycerol during SV40 Transformation , 1998, The Journal of Biological Chemistry.

[44]  D. Green,et al.  Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. , 1998, Blood.

[45]  A. Gotoh,et al.  Potential molecules implicated in downstream signaling pathways of p185BCR-ABL in Ph+ ALL involve GTPase-activating protein, phospholipase C-gamma 1, and phosphatidylinositol 3'-kinase. , 1994, Leukemia.

[46]  J. Osada,et al.  Microsomal sphingomyelin accumulation in thioacetamide-injured regenerating rat liver: involvement of sphingomyelin synthase activity. , 1993, Carcinogenesis.

[47]  Y. Hannun,et al.  Programmed cell death induced by ceramide. , 1993, Science.

[48]  D. Vance,et al.  Stimulation of sphingomyelin biosynthesis by brefeldin A and sphingomyelin breakdown by okadaic acid treatment of rat hepatocytes. , 1992, The Journal of biological chemistry.

[49]  E. Estey,et al.  Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  D. D. Jones,et al.  An update of the enzymology and regulation of sphingomyelin metabolism. , 1990, Biochimica et biophysica acta.

[51]  H. Kantarjian,et al.  Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high‐dose cytosine arabinoside , 1988, Cancer.

[52]  K. Wirtz,et al.  The synthesis of sphingomyelin in the Morris hepatomas 7777 and 5123D is restricted to the plasma membrane. , 1985, Biochimica et biophysica acta.

[53]  E. P. Kennedy,et al.  Cellular and enzymic synthesis of sphingomyelin. , 1982, Biochemistry.

[54]  J. Kanfer,et al.  The role of endogenous phosphatidylcholine and ceramide in the biosynthesis of sphingomyelin in mouse fibroblasts. , 1982, Biochimica et biophysica acta.

[55]  J. Bernert,et al.  Biosynthesis of sphingomyelin from erythro-ceramides and phosphatidylcholine by a microsomal cholinephosphotransferase. , 1981, Biochimica et biophysica acta.

[56]  J. Kanfer,et al.  The formation of sphingomyelin from phosphatidylcholine in plasma membrane preparations from mouse fibroblasts. , 1981, Biochimica et biophysica acta.

[57]  Y Nishizuka,et al.  Activation of calcium and phospholipid-dependent protein kinase by diacylglycerol, its possible relation to phosphatidylinositol turnover. , 1980, The Journal of biological chemistry.

[58]  Y. Nishizuka,et al.  Unsaturated diacylglycerol as a possible messenger for the activation of calcium-activated, phospholipid-dependent protein kinase system. , 1979, Biochemical and biophysical research communications.

[59]  N. Radin,et al.  The enzymatic formation of sphingomyelin from ceramide and lecithin in mouse liver. , 1974, The Journal of biological chemistry.

[60]  B. Ames,et al.  The role of polyamines in the neutralization of bacteriophage deoxyribonucleic acid. , 1960, The Journal of biological chemistry.